Auflistung nach Autor "Yalcin, K."
Anzeige der Dokumente 1-7 von 7
-
Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-alpha 2a treatment
Mederacke, I.; Yurdaydin, C.; Dalekos, G. N.; Bremer, B.; Erhardt, A.; Cakaloglu, Y.; Yalcin, K.; Gurel, S.; Zeuzem, S.; Zachou, K.; Bozkaya, H.; Dienes, H. P.; Manns, M. P.; Wedemeyer, H.; Hep-Net Int Delta Hepatitis, Study (2012)Background: The role of anti-HDV immunoglobulin M (IgM) testing in patients receiving pegylated interferon-alpha therapy for hepatitis delta is unknown. We performed anti-HDV IgM testing in a well defined cohort of HDVinfected ... -
ANTI-HDV-IGM TESTING IN HEPATITIS DELTA REVISITED: CORRELATIONS WITH DISEASE ACTIVITY AND RESPONSE TO PEGYLATED INTERFERON ALFA-2A TREATMENT
Mederacke, I.; Yurdaydin, C.; Bremer, B.; Cakaloglu, Y.; Erhardt, A.; Yalcin, K.; Zachou, K.; Gurel, S.; Heidrich, B.; Dalekos, G.; Dienes, H. P.; Manns, M. P.; Wedemeyer, H. (2010) -
Can response to pegylated interferon treatment in chronic delta hepatitis be predicted with on-treatment parameters?
Onder, F. O.; Erhardt, A.; Idilman, R.; Keskin, O.; Dalekos, G. N.; Yalcin, K.; Manns, M. P.; Wedemeyer, H.; Yurdaydin, C. (2012) -
Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta
Heidrich, B.; Yurdaydin, C.; Kabaçam, G.; Ratsch, B. A.; Zachou, K.; Bremer, B.; Dalekos, G. N.; Erhardt, A.; Tabak, F.; Yalcin, K.; Gürel, S.; Zeuzem, S.; Cornberg, M.; Bock, C. T.; Manns, M. P.; Wedemeyer, H. (2014)Interferon alpha is the only treatment option for hepatitis delta virus (HDV). Trials investigating the efficacy of pegylated interferon alpha (PEG-IFNa) showed HDV RNA negativity rates of 25-30% 24 weeks after therapy. ... -
LONG-TERM FOLLOW-UP AFTER PEG-IFNa2a-BASED THERAPY OF CHRONIC HEPATITIS DELTA
Heidrich, B.; Yurdaydin, C.; Kabacam, G.; Zachou, K.; Bremer, B.; Dalekos, G. N.; Erhardt, A.; Cakaloglu, Y.; Yalcin, K.; Gurel, S.; Zeuzem, S.; Bock, T.; Idilman, R.; Manns, M. P.; Wedemeyer, H. (2013) -
Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis
Kabacam, G.; Dalekos, G. N.; Cakaloglu, Y.; Zachou, K.; Bock, T.; Erhardt, A.; Zeuzem, S.; Tabak, F.; Yalcin, K.; Bozdayi, A. M.; Dienes, H. P.; Bozkaya, H.; Manns, M.; Wedemeyer, H.; Yurdaydin, C. (2012)Background/aims: The safety and efficacy of interferons in advanced delta hepatitis have not been explored. The aim of this subanalysis of a multi-center clinical trial was to compare the efficacy and safety of 48 weeks ... -
Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection
Mederacke, I.; Yurdaydin, C.; Großhennig, A.; Erhardt, A.; Cakaloglu, Y.; Yalcin, K.; Gurel, S.; Zeuzem, S.; Zachou, K.; Chatzikyrkou, C.; Bozkaya, H.; Dalekos, G. N.; Manns, M. P.; Wedemeyer, H. (2012)Long-term safety of treatment with hepatitis B virus (HBV) polymerase inhibitors is a concern. Adefovir dipivoxil (ADV) therapy has previously been associated with impairment of renal function. Limited data are available ...